Lytix Biopharma AS will release its first half and second quarter 2022 results
on August 25, 2022, 08.00 CEST.
 
The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme
Currie and CFO Gjest Breistein at 14:30 CEST. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live. Please register for the presentation at
https://forms.office.com/r/0nHms0PUdn

A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/financial-reports.html after the
presentation. 

For more information, please contact: Ole Peter Nordby,
ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief: Based in Oslo, Norway, Lytix is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient's immune system to fight cancer.
The Company's technology is based on pioneering research in "host defense
peptides" - nature's first line of defense towards foreign pathogens. Lytix
Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule
representing a new and superior therapeutic principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens and potent immunostimulants. This mode of action allows
cytotoxic T cells to recognize, infiltrate and attack cancer cells.